journal article·2022-08-31

Microsphere–Gel Composite System with Mesenchymal Stem Cell Recruitment, Antibacterial, and Immunomodulatory Properties Promote Bone Regeneration via Sequential Release of LL37 and W9 Peptides

Shiqing Ma, Chuanwen Wang, Yifan Dong, Wei Jing, Pengfei Wei, Cheng Peng, Zihao Liu, Bo Zhao, Yonglan Wang

ACS Applied Materials & Interfaces· Volume 14· Issue 34
Publisher page

Abstract

Various types of biomaterials have been widely used to treat complex bone defects. However, potential infection risks and inappropriate host immune responses induced by biomaterials can adversely affect the final bone repair outcome. Therefore, the development of novel bone biomaterials with antibacterial and immunomodulatory capabilities is conducive to achieving a good interaction between the host and material, thereby creating a local microenvironment favorable for osteogenesis and ultimately accelerating bone regeneration. In this study, we fabricated a porcine small intestinal submucosa (SIS) hydrogel containing LL37 peptides and polylactic-glycolic acid (PLGA) microspheres encapsulated with WP9QY(W9) peptide (LL37-W9/PLGA-SIS), which can fill irregular bone defects and exhibits excellent mechanical properties. In vitro experiments showed that the microsphere-gel composite system had sequential drug release characteristics. The LL37 peptide released first had good antibacterial performance and BMSC recruitment ability, which could prevent infection at an early stage and increase the number of BMSCs at the injured site. In addition, it also has immunomodulatory properties, showing both pro-inflammatory and anti-inflammatory activities, but its early pro-inflammatory properties are more inclined to activate the M1 phenotype of macrophages. Moreover, the subsequently released W9 peptide not only reduced the expression of pro-inflammatory genes to alleviate inflammation and induced more macrophages to convert to M2 phenotypes but also promoted the osteogenic differentiation of BMSCs. This finely regulated immune response is considered to be more closely related to the physiological bone healing process. When studying the interaction between macrophages and BMSCs mediated by the material, it was found that the immunomodulatory and osteogenic effects were enhanced. In vivo experiments, we constructed rat skull defect models, which further proved that LL37-W9/PLGA-SIS gel can properly regulate the immune response, and has a good ability to promote osteogenesis in situ. In conclusion, the LL37-W9/PLGA-SIS hydrogel has great application prospects in immune regulation and bone therapy.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Bone Tissue Engineering Materials · Graphene and Nanomaterials Applications · Nanoplatforms for cancer theranostics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Stomatology, The Second Hospital of Tianjin Medical University, Tianjin 300211, China

School and Hospital of Stomatology, Tianjin Medical University, Tianjin 30070, China

Beijing Biosis Healing Biological Technology Co., Ltd., Beijing 102600, China

Foshan (Southern China) Institute for New Materials, Foshan 528220, China

Funding

Tianjin Municipal Health Commission · Guangdong Science and Technology Department · Wu Jieping Medical Foundation · Tianjin Municipal Education Commission

References (55)

Show source-provided references
1. 10.1002/jbm.a.3683610.1002/jbm.a.36836 ↗
2. 10.1186/s40824-018-0138-610.1186/s40824-018-0138-6 ↗
3. 10.1038/boneres.2017.1410.1038/boneres.2017.14 ↗
4. 10.1016/j.dental.2019.04.00410.1016/j.dental.2019.04.004 ↗
5. 10.1177/204173141771207310.1177/2041731417712073 ↗
6. 10.1016/j.biomaterials.2021.12103710.1016/j.biomaterials.2021.121037 ↗
7. 10.1038/s41467-021-23005-210.1038/s41467-021-23005-2 ↗
8. 10.1016/j.addr.2021.11397010.1016/j.addr.2021.113970 ↗
9. 10.1016/j.smim.2016.10.00410.1016/j.smim.2016.10.004 ↗
10. 10.1186/s13287-016-0276-510.1186/s13287-016-0276-5 ↗
11. 10.7150/thno.4543410.7150/thno.45434 ↗
12. 10.1186/s13287-019-1447-y10.1186/s13287-019-1447-y ↗
13. 10.1038/s41377-020-00388-310.1038/s41377-020-00388-3 ↗
14. 10.1016/j.biomaterials.2021.12066710.1016/j.biomaterials.2021.120667 ↗
15. 10.3390/ijms2202078110.3390/ijms22020781 ↗
16. 10.1186/s13287-020-1578-110.1186/s13287-020-1578-1 ↗
17. 10.1007/s12015-013-9455-210.1007/s12015-013-9455-2 ↗
18. 10.1016/j.bone.2016.02.02010.1016/j.bone.2016.02.020 ↗
19. 10.1038/nrrheum.2012.110.1038/nrrheum.2012.1 ↗
20. 10.1016/j.drudis.2014.10.00310.1016/j.drudis.2014.10.003 ↗
21. 10.3389/fimmu.2019.0028310.3389/fimmu.2019.00283 ↗
22. 10.2147/ijn.s19858310.2147/ijn.s198583 ↗
23. 10.1016/j.actbio.2018.09.03610.1016/j.actbio.2018.09.036 ↗
24. 10.1073/pnas.090024410610.1073/pnas.0900244106 ↗
25. 10.3389/fimmu.2019.0292510.3389/fimmu.2019.02925 ↗
26. 10.1038/nm.386910.1038/nm.3869 ↗
27. 10.1016/j.ejps.2009.01.00210.1016/j.ejps.2009.01.002 ↗
28. 10.1016/j.bbrc.2017.11.05610.1016/j.bbrc.2017.11.056 ↗
29. 10.1016/j.ijpharm.2011.08.04710.1016/j.ijpharm.2011.08.047 ↗
30. 10.1016/j.biomaterials.2014.11.02810.1016/j.biomaterials.2014.11.028 ↗
31. 10.1089/ten.TEA.2011.054710.1089/ten.TEA.2011.0547 ↗
32. 10.1007/s40242-019-9177-310.1007/s40242-019-9177-3 ↗
33. 10.1016/j.biomaterials.2010.09.01710.1016/j.biomaterials.2010.09.017 ↗
34. 10.1002/1097-4636(20010605)55:3<304::aid-jbm1018>3.0.co;2-j10.1002/1097-4636(20010605)55:3<304::aid-jbm1018>3.0.co;2-j ↗
35. 10.1016/j.actbio.2018.09.03110.1016/j.actbio.2018.09.031 ↗
36. 10.1089/ten.teb.2012.043710.1089/ten.teb.2012.0437 ↗
37. 10.1016/j.actbio.2019.06.05710.1016/j.actbio.2019.06.057 ↗
38. 10.1007/s12015-014-9510-710.1007/s12015-014-9510-7 ↗
39. 10.1016/j.bpj.2011.02.01810.1016/j.bpj.2011.02.018 ↗
40. 10.1016/j.addr.2017.05.01010.1016/j.addr.2017.05.010 ↗
41. 10.1002/path.413310.1002/path.4133 ↗
42. 10.1016/j.pharep.2016.03.01510.1016/j.pharep.2016.03.015 ↗
43. 10.4049/jimmunol.130200510.4049/jimmunol.1302005 ↗
44. 10.1038/s41563-018-0190-610.1038/s41563-018-0190-6 ↗
45. 10.1080/2162402x.2019.168334710.1080/2162402x.2019.1683347 ↗
46. 10.1089/ten.TEA.2020.004110.1089/ten.TEA.2020.0041 ↗
47. 10.1016/j.bioactmat.2022.03.02110.1016/j.bioactmat.2022.03.021 ↗
48. 10.1016/j.cej.2021.13219710.1016/j.cej.2021.132197 ↗
49. 10.1039/d0tb02333g10.1039/d0tb02333g ↗
50. 10.1101/cshperspect.a02223610.1101/cshperspect.a022236 ↗
51. 10.1016/j.jvs.2018.09.04510.1016/j.jvs.2018.09.045 ↗
52. 10.1016/j.addr.2019.05.00510.1016/j.addr.2019.05.005 ↗
53. 10.1016/j.biomaterials.2014.06.06010.1016/j.biomaterials.2014.06.060 ↗
54. 10.1016/s0142-9612(02)00451-910.1016/s0142-9612(02)00451-9 ↗
55. 10.1002/elsc.20210004010.1002/elsc.202100040 ↗